Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease

Summary

This study is a randomized, non-blinded clinical trial specifically designed to assess the initial feasibility and efficacy of SGLT2 inhibitors in treating NAFLD among adults diagnosed with type 2 diabetes.

Timeline

Start

2024-02-15

Primary completion

2025-12-31

Completion

2025-12-31

Drugs

Indications